US5728536A
(en)
*
|
1993-07-29 |
1998-03-17 |
St. Jude Children's Research Hospital |
Jak kinases and regulation of Cytokine signal transduction
|
EP0672144A1
(en)
*
|
1992-10-20 |
1995-09-20 |
Chiron Corporation |
Interleukin-6 receptor antagonists
|
IT1261787B
(it)
*
|
1993-06-23 |
1996-06-03 |
Angeletti P Ist Richerche Bio |
Metodologia per la selezione di superagonisti, antagonisti e super- antagonisti di ormoni del cui complesso recettoriale fa parte gp 130.
|
US5470952A
(en)
*
|
1993-10-20 |
1995-11-28 |
Regeneron Pharmaceuticals, Inc. |
CNTF and IL-6 antagonists
|
AUPN024994A0
(en)
*
|
1994-12-23 |
1995-01-27 |
Ludwig Institute For Cancer Research |
Assay and peptides for use therein
|
US7070783B1
(en)
*
|
1995-05-09 |
2006-07-04 |
The Mathilda And Terence Kennedy Institute Of Rheumatology |
Small molecular weight TNF receptor multimeric molecule
|
US6217858B1
(en)
*
|
1997-02-11 |
2001-04-17 |
Hadasit & Medical Research Services & Development Company, Ltd. |
Pharmaceutical composition for treating hepatitis B virus (HBV) infection
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
WO1998002558A2
(en)
*
|
1996-07-17 |
1998-01-22 |
University Of Medicine And Dentistry Of New Jersey |
Chimeric receptors for jak-stat signal transduction
|
GB9621095D0
(en)
*
|
1996-10-09 |
1996-11-27 |
Imperial College |
Novel system
|
IT1288388B1
(it)
*
|
1996-11-19 |
1998-09-22 |
Angeletti P Ist Richerche Bio |
Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia
|
US6046158A
(en)
*
|
1996-12-20 |
2000-04-04 |
Board Of Regents The University Of Texas Systems |
Unique dendritic cell-associated C-type lectins, dectin-1 and dectin-2; compositions and uses thereof
|
SE9701010D0
(sv)
|
1997-03-19 |
1997-03-19 |
Pharmacia & Upjohn Ab |
Antibody
|
JPH10324639A
(ja)
|
1997-03-21 |
1998-12-08 |
Chugai Pharmaceut Co Ltd |
Il−6アンタゴニストを有効成分として含有する感作t細胞関与疾患の予防・治療剤
|
CA2318482C
(en)
|
1998-01-23 |
2010-04-13 |
Immunex Corporation |
Il-18 receptors
|
US6410245B1
(en)
|
1998-04-01 |
2002-06-25 |
Affymax, Inc. |
Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
|
US7083949B2
(en)
*
|
1998-09-25 |
2006-08-01 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6927044B2
(en)
*
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
US6864359B1
(en)
*
|
1999-02-11 |
2005-03-08 |
Xencor |
Structure-based screening techniques for drug discovery
|
US6800460B1
(en)
|
1999-03-11 |
2004-10-05 |
Schering Corporation |
Mammalian cytokine complexes
|
ES2319958T3
(es)
*
|
1999-03-11 |
2009-05-18 |
Schering Corporation |
Citoquinas de mamifero: reactivos y procedimientos asociados.
|
JP2003505514A
(ja)
*
|
1999-07-28 |
2003-02-12 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルベニア |
破骨細胞生成を阻害する方法
|
US6673771B1
(en)
*
|
1999-07-28 |
2004-01-06 |
The Trustees Of The University Of Pennsylvania |
Methods of inhibiting osteoclast activity
|
US6682739B1
(en)
*
|
1999-07-28 |
2004-01-27 |
The Trustees Of The University Of Pennsylvania |
Methods of inhibiting osteoclastogenesis
|
WO2001016166A2
(en)
|
1999-08-27 |
2001-03-08 |
The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Polypeptides, comprising il-6 ligand-binding receptor domains, and related nucleic acids, antibodies, compositions, and methods of use
|
WO2001025277A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Maxygen Aps |
Single-chain antagonist polypeptides
|
AU2002253942A1
(en)
*
|
2001-02-12 |
2002-08-28 |
Michael Amling |
Methods and compositions for control of bone formation via modulation of ciliary neurotrophic factor activity
|
US6864047B2
(en)
*
|
2001-03-29 |
2005-03-08 |
Mayo Foundation For Medical Education And Research |
IL1-β: a new target for myeloma therapy
|
US7595202B2
(en)
*
|
2001-04-23 |
2009-09-29 |
Teruyuki Nagamune |
Analysis method using reporter (label) intermolecular interaction
|
CA2446189C
(en)
|
2001-05-11 |
2011-10-18 |
Amgen, Inc. |
Peptides and related molecules that bind to tall-1
|
US20030125251A1
(en)
*
|
2001-06-21 |
2003-07-03 |
Wakefield Lalage M. |
Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 TNFR/Fc 융합 단백질, 상기 단백질을 코딩하는 DNA, 상기 DNA를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
EP1421189A2
(en)
*
|
2001-08-22 |
2004-05-26 |
Helix Biopharma Corp. |
Method and device for integrated protein expression, purification and detection
|
WO2003049673A2
(en)
|
2001-12-05 |
2003-06-19 |
Baylor College Of Medicine |
Methods and compositions for control of bone formation via modulation of sympathetic tone
|
US20040136992A1
(en)
|
2002-08-28 |
2004-07-15 |
Burton Paul B. J. |
Compositions and method for treating cardiovascular disease
|
ATE496066T1
(de)
*
|
2002-10-25 |
2011-02-15 |
Us Gov Health & Human Serv |
Verfahren zur prävention von tumorrezidiven durch blockade von tgf-beta
|
FI20031050A
(fi)
*
|
2003-07-09 |
2005-01-10 |
Valtion Teknillinen |
Menetelmä proteiinien katkaisuun
|
US20050069987A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Daly Thomas J. |
Modified ciliary neurotrophic factor polypeptides with reduced antigenicity
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
US8591885B2
(en)
|
2004-04-30 |
2013-11-26 |
Allergan, Inc. |
Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
|
WO2005110374A1
(en)
|
2004-04-30 |
2005-11-24 |
Allergan, Inc. |
Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
|
US20060182783A1
(en)
*
|
2004-04-30 |
2006-08-17 |
Allergan, Inc. |
Sustained release intraocular drug delivery systems
|
US7786261B2
(en)
*
|
2004-09-02 |
2010-08-31 |
National Research Council Of Canada |
Coiled-coil fusion proteins comprising cell receptor domains
|
WO2006089251A2
(en)
*
|
2005-02-17 |
2006-08-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SYNERGISTIC EFFECT OF TGF-β BLOCKADE AND IMMUNOGENIC AGENTS ON TUMORS
|
US8168584B2
(en)
|
2005-10-08 |
2012-05-01 |
Potentia Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration by compstatin and analogs thereof
|
WO2007061981A2
(en)
|
2005-11-21 |
2007-05-31 |
Lumera Corporation |
Surface plasmon resonance spectrometer with an actuator-driven angle scanning mechanism
|
US7463358B2
(en)
|
2005-12-06 |
2008-12-09 |
Lumera Corporation |
Highly stable surface plasmon resonance plates, microarrays, and methods
|
TWI381850B
(zh)
*
|
2005-12-30 |
2013-01-11 |
Pharmaessentia Corp |
藥物與聚合物之共軛物
|
US8637469B2
(en)
|
2006-07-11 |
2014-01-28 |
Roy C. Levitt |
Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
|
DK2068889T3
(da)
|
2006-08-10 |
2020-02-03 |
Roy C Levitt |
Anakinra til anvendelse i behandling af bronchiolitis obliterans syndrom
|
WO2008113185A1
(en)
|
2007-03-19 |
2008-09-25 |
National Research Counsil Of Canada |
Antagonists of ligands and uses thereof
|
US11078262B2
(en)
|
2007-04-30 |
2021-08-03 |
Allergan, Inc. |
High viscosity macromolecular compositions for treating ocular conditions
|
US8004669B1
(en)
|
2007-12-18 |
2011-08-23 |
Plexera Llc |
SPR apparatus with a high performance fluid delivery system
|
WO2010031168A1
(en)
*
|
2008-09-17 |
2010-03-25 |
National Research Council Of Canada |
HETERO-MULTIVALENT BINDING AGENTS FOR MEMBERS OF THE TGFβ SUPERFAMILY
|
CA2891673A1
(en)
|
2012-11-15 |
2014-05-22 |
Apellis Pharmaceuticals, Inc. |
Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
|
WO2014152391A1
(en)
|
2013-03-15 |
2014-09-25 |
Apellis Pharmaceuticals, Inc. |
Cell-penetrating compstatin analogs and uses thereof
|
EP3036262A4
(en)
|
2013-08-22 |
2017-03-01 |
Acceleron Pharma Inc. |
Tgf-beta receptor type ii variants and uses thereof
|
KR20180035884A
(ko)
|
2015-08-04 |
2018-04-06 |
악셀레론 파마 인코포레이티드 |
골수증식성 장애를 치료하기 위한 방법
|
CN117503905A
(zh)
|
2015-10-07 |
2024-02-06 |
阿佩利斯制药有限公司 |
给药方案
|
CA3059304A1
(en)
|
2017-04-07 |
2018-10-11 |
Apellis Pharmaceuticals, Inc. |
Dosing regimens and related compositions and methods
|
WO2018195388A1
(en)
|
2017-04-21 |
2018-10-25 |
Kindred Biosciences, Inc. |
Il4/il13 receptor molecule for veterinary use
|
KR20240023201A
(ko)
|
2017-05-04 |
2024-02-20 |
악셀레론 파마 인코포레이티드 |
Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
|
WO2019173692A2
(en)
|
2018-03-09 |
2019-09-12 |
Agenus Inc. |
Anti-cd73 antibodies and methods of use thereof
|
WO2020035482A1
(en)
|
2018-08-13 |
2020-02-20 |
Iltoo Pharma |
Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
|